Business Hours
M-Su Closed
Languages
Bengali, French
Listed In: Family Doctors Associations
I am building a career in both clinical and translational research of brain tumors, primary and those resulting from metastasis. Clinically, I primarily see adult brain tumor patients and conduct/initiate clinical trials to meet the needs of this patient population. On the research side, I have a… I am building a career in both clinical and translational research of brain tumors, primary and those resulting from metastasis. Clinically, I primarily see adult brain tumor patients and conduct/initiate clinical trials to meet the needs of this patient population. On the research side, I have a long-standing research interest in clinically important membrane transport proteins. I conducted genetic and biochemical research on transporters, channels, and pumps during my doctoral research at the University of Cambridge, my postdoctoral study at Yale University, and various institutions (Yale, Johns Hopkins University, Cambridge) while training in medicine at Cambridge. Membrane transport proteins I have worked on include the proton-ATPase (mentor: C. Slayman) and the TAP transporter (mentor: P. Lehner), critical to antigen processing. After receiving my medical degree, I pursued advanced medical and additional research training in the U.S. (Johns Hopkins, Harvard) and received continuous funding from the NIH to pursue this research (NINDS-R25, NCI-K12, NINDS-K08). My first independent appointment as an Assistant Professor, Neuro-oncologist was at Emory University in 2016. At the University of Cincinnati, I was the Associate Director of the UC Brain Tumor Center and a recipient of the Harold C. Schott Endowed Chair. When I was at UNC, I was the Vice-Chair of Research in Neurosurgery and the first recipient of the Mayfield Scholar Award, which covers 60% of my time for research. At this time, my lab is focused on (1) the development of a therapeutic approach for the treatment of primary and pediatric brain tumors, as well as cancers that commonly metastasize to the CNS (lung and melanoma), and (2) translation of technological advances that may impact treatment and quality of life in patients with cancer. Read more